Complications drive much of the decision-making in implant-based breast reconstruction, and two of the levers surgeons control are material selection and adjunctive fat grafting. This article reviews the main complication categories and how matrix choice and technique relate to them, at a general professional level. It is not clinical guidance; complication management should follow current evidence and local protocols.
The complications that matter most
Seroma
Fluid collection is one of the more discussed matrix-associated complications. Contributing factors include dead space, matrix surface area and host response. Mitigations commonly focus on haemostasis, fixation, drain management and appropriate matrix selection and preparation. A matrix that apposes and integrates well, rather than sitting as an inert sheet, is theoretically favourable here.
Infection
Infection in the setting of an implant is consequential and can lead to device loss. Sterile handling and processing per IFU, sound flap perfusion and dead-space control are central. The material’s sterilisation method and biological cleanliness are relevant selection factors.
Mastectomy skin-flap necrosis
Largely a function of flap perfusion and patient factors rather than the matrix itself, but it interacts with technique: a device close to the skin under a compromised flap is a set-up for exposure. This underscores selection and perfusion assessment.
Capsular contracture and rippling
Biological support is often argued to influence the capsular response, and adequate soft-tissue coverage — matrix plus fat — reduces the visibility of rippling and edges. These are areas where the matrix-and-fat combination is most visibly beneficial to contour.
How matrix selection interacts with complications
No matrix eliminates complications, but properties plausibly shift risk profiles: mechanical strength and suture retention affect pocket stability; decellularisation quality and source tissue affect integration and host response; sterility and processing affect infection risk; and consistency affects predictability. Because these properties vary between products, complication data from one matrix should not be assumed to transfer to another — a point covered in our evidence appraisal article. A pericardium-derived, integration-oriented design such as ExaShape is intended to support the pocket while encouraging revascularisation and repopulation.
The irradiated field
Radiotherapy deserves separate attention because it materially changes the risk landscape: impaired healing, higher rates of some complications, and altered capsular behaviour. Matrix and technique choices that are reasonable in a non-irradiated setting may need to be reconsidered when radiotherapy is planned or has been delivered. Whether prepectoral placement, the specific matrix, and the timing of any fat grafting are appropriate in an irradiated field are decisions that should draw on current evidence for that specific scenario rather than general series.
The role of fat grafting
Adjunctive fat grafting addresses the coverage-related complications — rippling, edge visibility, thin-flap contour — by adding autologous soft tissue. Its benefit depends on graft survival, which is influenced by gentle harvest and clean processing that preserves the SVF; this is the rationale behind closed-loop fat dialysis systems such as EXAFAT.
Controllable levers, in summary
Although complications are multifactorial and never fully eliminable, the levers a surgeon most directly controls are worth stating plainly: rigorous patient selection and flap-perfusion assessment; a matrix chosen on its specific mechanical, biological and processing properties; meticulous haemostasis, dead-space and drain management; sterile handling per IFU; and appropriate use of adjunctive fat grafting for coverage. Getting these fundamentals right consistently tends to matter more than any single product choice in isolation.
The bottom line
Complication reduction in implant-based reconstruction is multifactorial, but material selection and fat grafting are meaningful, controllable levers. Choosing a matrix on its specific mechanical, biological and processing properties — and pairing structural support with well-processed fat grafting — is a rational strategy. Related reading: matrix vs. ADM vs. mesh and the prepectoral technique overview.
This is a general professional overview, not clinical guidance. Follow current evidence and local protocols for complication prevention and management.
Important information This article is general education, not medical advice. Tap to read the full medical, regulatory & legal notice.
This article is provided by Advanced Biomedical Concept for general informational and educational purposes only. It does not constitute medical, surgical, diagnostic, or other professional healthcare advice, and it is not a substitute for consultation with a suitably qualified healthcare professional. Reading it creates no doctor–patient or other professional relationship. Nothing here should be used to diagnose, treat, cure, or prevent any disease or condition, or to make decisions about medical care. Always seek the advice of a physician or other qualified provider with any questions about a medical condition or treatment, and never disregard or delay professional advice because of something you have read here.
Any reference to Advanced Biomedical Concept products (including ExaShape and ExaFat) is provided for general information only. These are medical devices intended to be used by appropriately trained healthcare professionals strictly in accordance with their applicable, current Instructions for Use (IFU). Regulatory status (including CE marking and classification under the EU Medical Device Regulation), market availability, and approved indications differ between countries and may change over time; a device referred to here may not be available or approved in your country. This content is not intended as, and must not be relied upon as, a statement or claim of safety, clinical performance, or efficacy beyond what is set out in the applicable IFU and current regulatory approvals. Product-specific information is directed at healthcare professionals and is not intended to promote, advertise, or offer any medical device to the general public where such promotion is restricted or prohibited by law.
Statements reflect information believed to be accurate at the date of publication and may be updated or corrected without notice. Any statements regarding the future are expectations or general views, not guarantees. Clinical outcomes depend on many individual factors, results vary from person to person, and no particular result is promised or implied. Where third-party studies, sources, or external links are referenced, they are provided for convenience and information only and do not imply endorsement, and Advanced Biomedical Concept is not responsible for their content.
To the fullest extent permitted by applicable law, Advanced Biomedical Concept and its officers, employees, contributors, and representatives (each acting in that capacity and on behalf of Advanced Biomedical Concept) accept no liability for any loss, injury, or damage of any kind arising directly or indirectly from use of, or reliance on, this content. Nothing in this notice excludes or limits any liability that cannot lawfully be excluded or limited.
Questions about this material can be directed to us via our contact page.
Last reviewed: July 23, 2026.
